Prescription medication · Rapid-Acting Insulin
insulin lispro
Also sold as Humalog. Admelog is used to improve blood sugar control in people with diabetes.
Data updated 2026-05-15
- 134,198
- FDA reportsHeavily reported
- 11
- InteractionsSeveral interactions
- 1
- Recall record
What the data shows
insulin lispro (Humalog) is a prescription Rapid-Acting Insulin, more reported than roughly 9 in 10 tracked drugs (134,198 FDA reports), with 11 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
insulin lispro (Humalog) is a prescription Rapid-Acting Insulin. Admelog is used to improve blood sugar control in people with diabetes.
Admelog is a rapid-acting insulin that helps control blood sugar levels. It is used to treat diabetes in adults and children.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$9.80/unit
Generic Price
$10.20/unit
Generic Available
Yes (0 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Admelog is used to improve blood sugar control in people with diabetes.
Common side effects
Common cold, Upper respiratory infection
Key warnings
Never share your Admelog SoloStar pen or syringe with anyone else, even if you change the needle.
The sections below are summarized in plain English from insulin lispro's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Admelog is a man-made insulin that works like the insulin your body should be making. It helps sugar move from your blood into your cells. This lowers your blood sugar levels.
Side Effects (from patient reports)
Based on 134,198 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for insulin lispro, by number of reports
- Blood Glucose Increased
Blood Glucose Increased
38,180 reports
- Incorrect Dose Administered 9,067
Incorrect Dose Administered
9,067 reports
- Blood Glucose Decreased 8,761
Blood Glucose Decreased
8,761 reports
- Visual Impairment 5,392
Visual Impairment
5,392 reports
- Nausea 4,787
Nausea
4,787 reports
- Malaise 3,946
Malaise
3,946 reports
- Hypoglycaemia 3,800
Hypoglycaemia
3,800 reports
- Fatigue 3,754
Fatigue
3,754 reports
- Drug Dose Omission 3,751
Drug Dose Omission
3,751 reports
- Fall 3,428
Fall
3,428 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for insulin lispro each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where insulin lispro sits
insulin lispro has more FDA adverse-event reports than 91% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is insulin lispro; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 134,198 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
134,198
Reports Mentioning Death
5,906
4.4% of reports — not proof of cause
Hospitalization Reports
33,389
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | BLOOD GLUCOSE INCREASED | 38,180 |
| 2 | INCORRECT DOSE ADMINISTERED | 9,067 |
| 3 | BLOOD GLUCOSE DECREASED | 8,761 |
| 5 | VISUAL IMPAIRMENT | 5,392 |
| 6 | NAUSEA | 4,787 |
| 7 | MALAISE | 3,946 |
| 8 | HYPOGLYCAEMIA | 3,800 |
| 9 | FATIGUE | 3,754 |
| 10 | DRUG DOSE OMISSION | 3,751 |
| 11 | FALL | 3,428 |
| 12 | UNDERDOSE | 3,374 |
| 13 | DIARRHOEA | 3,156 |
| 14 | GLYCOSYLATED HAEMOGLOBIN INCREASED | 3,144 |
| 15 | VOMITING | 3,121 |
| 16 | PAIN | 3,088 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Never share your Admelog SoloStar pen or syringe with anyone else, even if you change the needle. Sharing can spread blood-borne diseases. Changes in your insulin plan can cause high or low blood sugar. Make these changes carefully with your doctor's help. Low blood sugar can be life-threatening. Watch your blood sugar closely.
Known Drug Interactions
Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline,...
Mechanism: Fluoxetine can increase the blood-sugar-lowering effect of insulin, which raises the risk of your blood sugar dropping too low.
Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline,...
Mechanism: Both of these medicines lower blood sugar, so taking them together increases the chance of having dangerously low blood sugar.
Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline,...
Mechanism: Octreotide can make insulin work more strongly or lower blood sugar on its own, which increases the risk of hypoglycemia.
Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral...
Mechanism: Albuterol can make insulin less effective at lowering your blood sugar levels.
Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine. Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine ( 7 ).
Mechanism: Clonidine can change how insulin affects your blood sugar and may hide the physical signs of low blood sugar.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I do if my insulin pump malfunctions?
Can I mix Admelog with other insulins?
How often should I change the Admelog in my insulin pump?
What if I see particles or color in my Admelog?
Can changes to my insulin plan affect my blood sugar?
What should I do if I keep injecting into the same spot?
How often should I check my blood sugar?
What happens if I take too much Admelog?
What happens if I don't take enough Admelog?
Can other medicines affect Admelog?
What are the common side effects of insulin lispro?
Does insulin lispro interact with other medications?
What drug class is insulin lispro?
What pregnancy or breastfeeding source fields are listed for insulin lispro?
Has insulin lispro been recalled?
Active Recalls
Lack of Assurance of Sterility: Malformed crimped collar seal
Sanofi-Aventis U.S. LLC
Related Medications in Rapid-Acting Insulin
Other drugs grouped near insulin lispro - same-class peers and common alternatives.
acarbose
Precose
Acarbose is a medicine that helps lower blood sugar levels in people with type 2 diabetes.
Compare with insulin lispro →
alogliptin
Nesina
Compare with insulin lispro →
bromocriptine
Cycloset
Bromocriptine (Cycloset) is a medicine that acts like dopamine in your body.
Compare with insulin lispro →
canagliflozin
Invokana
Invokana is a medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Compare with insulin lispro →
colesevelam
Welchol
Colesevelam is a medicine that helps lower bad cholesterol (LDL-C) and control blood sugar in adults.
Compare with insulin lispro →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for insulin lispro: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 134,198.
- spironolactone Δ 202 reports · Potassium-Sparing Diuretic / Aldosterone Antagonist 133,996reports
- escitalopram Δ 338 reports · Selective Serotonin Reuptake Inhibitor (SSRI) 134,536reports
- citalopram Δ 685 reports · Selective Serotonin Reuptake Inhibitor (SSRI) 133,513reports
- abatacept Δ 971 reports · T-Cell Co-Stimulation Modulator 133,227reports
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 4.40%.
- ciclesonide Δ 0.00 pts · 13,075 reports · Inhaled Corticosteroid 4.41%death share
- naltrexone Δ 0.04 pts · 29,813 reports · Opioid Antagonist 4.36%death share
- loratadine Δ 0.05 pts · 104,378 reports · Second-Generation Antihistamine 4.35%death share
- testosterone Δ 0.12 pts · 40,954 reports · Androgen Hormone 4.52%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on insulin lispro
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for insulin lispro
The FDA label for insulin lispro (sold under brand names such as Humalog) classifies it as a prescription-only medication in the Rapid-Acting Insulin class. Admelog is used to improve blood sugar control in people with diabetes. Official labeling lists 2 commonly reported side effects, including Common cold, Upper respiratory infection.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 134,198 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $10.20 versus $9.80 for the brand.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: June 4, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages